Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.22 USD
Change Today -0.01 / -0.45%
Volume 1.1M
AMRN On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 12:33 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

amarin corp plc -adr (AMRN) Snapshot

Open
$2.21
Previous Close
$2.23
Day High
$2.34
Day Low
$2.20
52 Week High
03/16/15 - $3.33
52 Week Low
11/11/14 - $0.78
Market Cap
407.1M
Average Volume 10 Days
2.0M
EPS TTM
$-0.32
Shares Outstanding
183.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMARIN CORP PLC -ADR (AMRN)

amarin corp plc -adr (AMRN) Related Businessweek News

No Related Businessweek News Found

amarin corp plc -adr (AMRN) Details

Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product includes Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

201 Employees
Last Reported Date: 03/3/15
Founded in 1989

amarin corp plc -adr (AMRN) Top Compensated Officers

Chief Executive Officer, President, Assistant...
Total Annual Compensation: $500.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $212.5K
Senior Vice President and President of Resear...
Total Annual Compensation: $404.8K
Executive Vice President of Strategic Initiat...
Total Annual Compensation: $400.9K
Compensation as of Fiscal Year 2014.

amarin corp plc -adr (AMRN) Key Developments

Amarin Corporation Announces Encore Presentation of Results of the Apolipoprotein C-iii - Post-Hoc Analysis from Marine and Anchor Studies of Vascepa

Amarin Corporation plc announced the encore presentation of findings from a post-hoc analysis examining the effects of icosapent ethyl (VascepaA(R)) on Apolipoprotein C-III (ApoC-III) levels in both very high triglyceride (VHTG) and high triglyceride (HTG) patient populations. The poster titled, "Icosapent Ethyl (eicosapentaenoic acid ethyl ester): Effects on Apolipoprotein C-III in Patients from the MARINE and ANCHOR Studies," will be on display at the European Society of Cardiology 2015 Annual Congress in London, England, Session 302 Poster Session #2. The results will be presented by lead investigator, Dr. Christie Ballantyne, Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center on August 30, 2015. The analysis evaluated the effects of EPA-only prescription Vascepa, alone or in combination with statin therapy, on ApoC-III levels in 148 patients with VHTG levels in the MARINE study of Vascepa and 612 patients with HTG levels in the ANCHOR study of Vascepa. In Marine, Vascepa 4 g/day statistically significantly reduced ApoC-III levels by 25.1% (P (0.0001) versus placebo. In Anchor, Vascepa 4 g/day statistically significantly reduced ApoC-III levels by 19.2% (P (0.0001) versus placebo. The findings, originally presented at the National Lipid Association Annual Scientific Sessions in 2014, show that at both 4g/day and 2g/day compared to placebo, Vascepa, alone or in combination with statin therapy, significantly reduced ApoC-III levels in adult patients in the MARINE and ANCHOR studies, in which Vascepa also significantly lowered TG levels without raising LDL-C. Further study is needed to determine if the effects of Vascepa, including those on ApoC-III, in patients with hypertriglyceridemia would have clinically meaningful benefit in the human body. About Vascepaa(R) (icosapent ethyl) capsules VASCEPAA(R) (icosapent ethyl) capsules, known in scientific literature as AMR101, is a highly pure-EPA omega-3 prescription product in a 1 gram capsule. VASCEPA (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (a0/00500 mg/dL) hypertriglyceridemia. The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.

Amarin Corporation plc Promotes Joseph T. Kennedy to Executive Vice President, General Counsel and Strategic Initiatives

Amarin Corporation plc announced the promotion of Joseph T. Kennedy to Executive Vice President, General Counsel and Strategic Initiatives. With more than 20 years of industry experience, Mr. Kennedy has contributed significantly to progress at the company since joining the company in December 2011 as Senior Vice President, General Counsel. He also played an important role supporting Amarin business development in the establishment of Amarin's U.S. Vascepa co-promotion agreement with Kowa Pharmaceutical America Inc. and collaboration agreement with Eddingpharm in greater China. Mr. Kennedy joined the company with an impressive record of achievement in the life science industry.

Amarin Corporation plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Amarin Corporation plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total net revenues of USD 17,707,000 compared to USD 12,606,000 a year ago. Operating loss was USD 26,737,000 compared to USD 25,240,000 a year ago. Loss from operations before taxes was USD 32,049,000 compared to income from operations before taxes of USD 15,734,000 a year ago. Net loss was USD 31,512,000 compared to net income of USD 15,323,000 a year ago. Net loss applicable to common shareholders was USD 62,853,000 or USD 0.35 basic and diluted per share compared to net income applicable to common shareholders of USD 15,323,000 or USD 0.08 per diluted per share a year ago. Non-GAAP Adjusted net loss was USD 27,696,000 or USD 0.15 per basic and diluted share compared to USD 23,433,000 or USD 0.14 per basic and diluted share a year ago. For the six months, total net revenues were USD 33,640,000 compared to USD 23,573,000 a year ago. Operating loss was USD 53,786,000 compared to USD 50,811,000 a year ago. Loss before income taxes was USD 63,647,000 compared to USD 9,821,000 a year ago. Net loss was USD 62,638,000 compared to USD 10,657,000 a year ago. Net loss applicable to common shareholders was USD 94,847,000 or USD 0.53 basic and diluted per share compared to USD 10,657,000 or USD 0.07 per diluted per share a year ago. Non-GAAP Adjusted net loss was USD 56,253,000 or USD 0.32 per basic and diluted share compared to USD 51,921,000 or USD 0.30 per basic and diluted share a year ago. The company has lowered net cash used in operating activities to USD 37.6 million in the six months ended June 30, 2015 compared to USD 38.8 million in the same period in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMRN:US $2.22 USD -0.01

AMRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $61.21 USD -1.94
Enzymotec Ltd $9.98 USD +0.29
Incyte Corp $119.22 USD -0.71
Jazz Pharmaceuticals PLC $170.88 USD -1.95
Momenta Pharmaceuticals Inc $19.66 USD -0.71
View Industry Companies
 

Industry Analysis

AMRN

Industry Average

Valuation AMRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMARIN CORP PLC -ADR, please visit www.amarincorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.